Topotecan and Melphalan for Retinoblastoma

Summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Eligibility

Inclusion Criteria:

* diagnosed as retinoblastoma
* receiving eyeball-sparing treatment

Exclusion Criteria:

* disease progression during follow-up

Conditions3

Interventions2

Related trials

• Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning — University of Liege
• Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients — Insel Gruppe AG, University Hospital Bern
• Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan — Shanghai Jiao Tong University School of Medicine
• High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) — St. Anna Kinderkrebsforschung
• Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma — Eye & ENT Hospital of Fudan University
• Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• A Study to Give Treatment Inside the Eye to Treat Retinoblastoma — Children's Oncology Group
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma — National Cancer Institute (NCI)

Browse More Trials